↓ Skip to main content

Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency

Overview of attention for article published in Therapeutics and Clinical Risk Management, July 2009
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

wikipedia
2 Wikipedia pages

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency
Published in
Therapeutics and Clinical Risk Management, July 2009
DOI 10.2147/tcrm.s6178
Pubmed ID
Authors

Cappa, Danilo Fintini, Claudia Brufani

Abstract

Growth hormone insensitivity syndrome (GHI) or insulin-like growth factor-1 (IGF-1) deficiency (IGFD) is characterized by deficit of IGF-1 production due to alteration of response of growth hormone (GH) receptor to GH. This syndrome is due to mutation of GH receptor or IGF-1 gene and patients affected showed no response to GH therapy. The only treatment is recombinant IGF-1 (mecasermin), which has been available since 1986, but approved in the United States by the US Food and Drug Administration only in 2005 and in Europe by the European Medicines Agency in 2007. To date, few studies are available on long-term treatment with mecasermin in IGFD patients and some of them have a very small number of subjects. In this review we discuss briefly clinical features of severe primary IGFD, laboratory findings, and indications for treatment. Results of long-term therapy with rhIGF1 (mecasermin) in patients affected by severe primary IGFD and possible side effects are explained.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 10%
Student > Ph. D. Student 1 5%
Student > Master 1 5%
Unknown 16 80%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 10%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Nursing and Health Professions 1 5%
Unknown 16 80%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2014.
All research outputs
#816,502
of 3,629,407 outputs
Outputs from Therapeutics and Clinical Risk Management
#81
of 268 outputs
Outputs of similar age
#24,800
of 95,349 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#3
of 15 outputs
Altmetric has tracked 3,629,407 research outputs across all sources so far. This one has received more attention than most of these and is in the 63rd percentile.
So far Altmetric has tracked 268 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,349 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.